Literature DB >> 17850325

The economics of haemophilia prophylaxis: governmental and insurer perspectives. Proceedings of the Second International Prophylaxis Study Group (IPSG) symposium.

B M Feldman1, L Aledort, M Bullinger, F M Delaney, A S Doria, S Funk, P Giangrande, B Lundin, M Manco-Johnson, A Miners, P C Scriba, A Srivastava, W Schramm, V S Blanchette.   

Abstract

Entities:  

Mesh：

Year:  2007        PMID： 17850325     DOI： 10.1111/j.1365-2516.2007.01542.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN： 1351-8216            Impact factor:   4.287


× No keyword cloud information.
  4 in total

1.  A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients.

Authors:  Hendrika Hazendonk; Karin Fijnvandraat; Janske Lock; Mariëtte Driessens; Felix van der Meer; Karina Meijer; Marieke Kruip; Britta Laros-van Gorkom; Marjolein Peters; Saskia de Wildt; Frank Leebeek; Marjon Cnossen; Ron Mathôt
Journal:  Haematologica       Date:  2016-07-06       Impact factor: 9.941

2.  Using value-of-information methods when the disease is rare and the treatment is expensive--the example of hemophilia A.

Authors:  Lusine Abrahamyan; Andrew R Willan; Joseph Beyene; Marjorie Mclimont; Victor Blanchette; Brian M Feldman
Journal:  J Gen Intern Med       Date:  2014-08       Impact factor: 5.128

3.  Measuring the quality of haemophilia care across different settings: a set of performance indicators derived from demographics data.

Authors:  A Iorio; J S Stonebraker; M Brooker; J M Soucie
Journal:  Haemophilia       Date:  2016-12-08       Impact factor: 4.287

Review 4.  Modern Treatments of Haemophilia: Review of Cost-Effectiveness Analyses and Future Directions.

Authors:  Paolo A Cortesi; Lucia S D'Angiolella; Alessandra Lafranconi; Mariangela Micale; Giancarlo Cesana; Lorenzo G Mantovani
Journal:  Pharmacoeconomics       Date:  2018-03       Impact factor: 4.981
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.